293 related articles for article (PubMed ID: 27344327)
1. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.
Escalante CP; Chang YC; Liao K; Rouleau T; Halm J; Bossi P; Bhadriraju S; Brito-Dellan N; Sahai S; Yusuf SW; Zalpour A; Elting LS;
Support Care Cancer; 2016 Sep; 24(9):4057-74. PubMed ID: 27344327
[TBL] [Abstract][Full Text] [Related]
2. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis.
Elting LS; Chang YC; Parelkar P; Boers-Doets CB; Michelet M; Hita G; Rouleau T; Cooksley C; Halm J; Vithala M; Bossi P; Escalante C; Brennan MT;
Support Care Cancer; 2013 Nov; 21(11):3243-54. PubMed ID: 23636648
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Future Oncol; 2014 Oct; 10(12):1981-92. PubMed ID: 25386814
[TBL] [Abstract][Full Text] [Related]
4. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
Bria E; Cuppone F; Fornier M; Nisticò C; Carlini P; Milella M; Sperduti I; Terzoli E; Cognetti F; Giannarelli D
Breast Cancer Res Treat; 2008 May; 109(2):231-9. PubMed ID: 17638068
[TBL] [Abstract][Full Text] [Related]
6. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
7. Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients.
Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
Am J Ther; 2017; 24(1):e81-e101. PubMed ID: 26322676
[TBL] [Abstract][Full Text] [Related]
8. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
9. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews.
Van Leeuwen MT; Luu S; Gurney H; Brown MR; Pearson SA; Webber K; Hunt L; Hong S; Delaney GP; Vajdic CM
JNCI Cancer Spectr; 2020 Dec; 4(6):pkaa076. PubMed ID: 33392444
[TBL] [Abstract][Full Text] [Related]
11. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Richards CJ; Je Y; Schutz FA; Heng DY; Dallabrida SM; Moslehi JJ; Choueiri TK
J Clin Oncol; 2011 Sep; 29(25):3450-6. PubMed ID: 21810682
[TBL] [Abstract][Full Text] [Related]
13. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.
Lancet; 1997 Nov; 350(9089):1417-24. PubMed ID: 9371164
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Wu S; Chen JJ; Kudelka A; Lu J; Zhu X
Lancet Oncol; 2008 Feb; 9(2):117-23. PubMed ID: 18221915
[TBL] [Abstract][Full Text] [Related]
15. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
Schutz FA; Je Y; Choueiri TK
Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.
Brown SA; Nhola L; Herrmann J
Clin Pharmacol Ther; 2017 Jan; 101(1):65-80. PubMed ID: 27806435
[TBL] [Abstract][Full Text] [Related]
17. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.
Russo G; Cioffi G; Gori S; Tuccia F; Boccardi L; Khoury G; Lestuzzi C; Maurea N; Oliva S; Faggiano P; Tarantini L;
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):141-6. PubMed ID: 24534802
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
Jang S; Zheng C; Tsai HT; Fu AZ; Barac A; Atkins MB; Freedman AN; Minasian L; Potosky AL
Cancer; 2016 Jan; 122(1):124-30. PubMed ID: 26439451
[TBL] [Abstract][Full Text] [Related]
19. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
20. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.
Chen T; Xu T; Li Y; Liang C; Chen J; Lu Y; Wu Z; Wu S
Cancer Treat Rev; 2011 Jun; 37(4):312-20. PubMed ID: 20952131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
